RxDoctor Payments Data

Aaron Greene

Physician Assistant · Petoskey, MINPI 1598902314

Payments from drug & device makers

$5,531in general payments, 2019–2025

Across 281 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$916
  • Lundbeck LLC$818
  • Alkermes, Inc.$596
  • Neurocrine Biosciences, Inc.$484
  • Axsome Therapeutics, Inc.$347
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$5,531100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,531 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$12,053
Medicare patients
15
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$23,712
RexultiBrexpiprazole15$20,925
Vilazodone Hcl20$2,223
Desvenlafaxine Succinate ErDesvenlafaxine Succinate54$2,002
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine17$834
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$645
Trazodone Hcl34$645
Divalproex Sodium ErDivalproex Sodium12$589
Aripiprazole40$513
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$333
Methylphenidate Hcl16$320
Escitalopram Oxalate38$238
Methadone Hcl11$235
Olanzapine30$212
Duloxetine Hcl19$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$916$23,71218 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,049$20,92515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Petoskey

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →